New Taipei City, Taiwan, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that it has entered into a non-binding Memorandum of Understanding (the "MOU") with a Vietnam-based pharmaceutical distribution company headquartered in Ho Chi Minh City, to evaluate the development and commercialization of MCS-2 in the Vietnam pharmaceutical market.
Under the terms of the MOU, Jyong Biotech and the Vietnam pharmaceutical distribution company will proceed with due diligence and discussions to determine the scope and structure of any definitive collaboration, including commercial strategy, regulatory pathway and local market execution. There can be no assurance that any definitive agreement will be reached or that any contemplated collaboration will be consummated.
Fu Feng Kuo, CEO and Chairwoman of Jyong Biotech, commented, "This MOU represents an important step in our Asia-focused strategy to bring plant-derived MCS therapies to new markets. Vietnam presents meaningful opportunities for patient access and local partnership, and we are committed to working closely with our prospective partner to evaluate viable regulatory and commercial pathways while safeguarding the scientific and clinical integrity of MCS-2."
The MOU follows Jyong Biotech's previously announced non-binding Letter of Intent with a South Korean pharmaceutical company to evaluate in-licensing and development opportunities for plant-derived MCS products, announced on November 24, 2025.
As of present day, MCS-2 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.
About Jyong Biotech Ltd.
Headquartered in Taiwan, Jyong Biotech Ltd. is a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, BOTRESO®, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers' health needs and seeks to be a valuable business organization that is held in high esteem by the public.
For more information, please visit: https://www.jyongbio.com/, https://jyongir.com/.
Forward-Looking Statement
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the "Risk Factors" section of the registration statement, prospectuses, annual and interim reports, and other filings with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For more information, please contact:
Jyong Biotech Ltd.
ir@jyongbio.com
Investor Relations
WFS Investor Relations Inc.
Email: services@wealthfsllc.com
Phone: +1 628 283 9214
